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Vaccination  against  disease  aims  at  the induction  of  long-lasting  cellular  and  humoral  immune  responses.
Few  studies  have  addressed  the mechanisms  by which  meningococcal  vaccines  generate  and  sustain
immunological  memory.  The  goal  of  this  study  was  to investigate  the  development  of  long-term  humoral
and  cellular  memory  to Neisseria  meningitidis  serogroup  B  (MenB)  in  health  subjects  after  immunisation
with  the  Cuban  outer  membrane  protein  (OMP)  vaccine  (VA-MENGOC-BC®). The  results  showed  that
three  doses  of  vaccine  were  necessary  to induce  a detectable  memory  B-cell  response  (mean  of  0.46%)
which  became  undetectable  6 months  later.  After boosting,  only  2 of 5 individuals  responded  with  an
increase  in memory  B-cell  frequencies  (values  of 0.15%  and  0.34%).  Bactericidal  and opsonic  antibody  lev-
els  were  higher  after  primary  immunisation  (log2 mean  and  median  of  4.7  and  1212,  respectively)  when
compared  with  post-booster  response  (log2 mean  of 2.6  and  median  of  285,  respectively).  Together,  these
data  suggest  a  failure  of  vaccine  to  induce  long-term  memory  B-cell  and  serological  memory  in adults.
However,  we  observed  a signiﬁcant  and  functional  memory  T-cell  response  specially  after boosting,  with
a  predominance  of activated  (CD69+) central  memory  T-cell  (CD4+CD45−CCR7+)  response.  Therefore,  this
study  suggests  that  vaccination  with  the  MenB  vaccine  induced  the  generation  and  activation  of  memory
T-cells  but  failed  to maintain  the  memory  B-cell  population  at a stable  size  and/or  function.. Introduction
Neisseria meningitidis is a human pathogen and one of the major
auses of bacterial meningitis [1]. Polysaccharide vaccines available
oth in protein conjugated and non-conjugated form, have been
ntroduced against capsular serogroups A, C,W-135 and Y, but are
neffective against serogroup B meningococci, which cause a signif-
cant burden of disease in many parts of the world. Detoxiﬁed outer
embrane vesicles have been used for decades to elicit protection
gainst epidemic serogroup B disease [2].
Considerable evidence indicates that complement-mediated
erum  bactericidal antibody (SBA), induced by nasopharyngeal col-
nization or vaccination, confers protection against MenB [3,4].
oluble antibodies maintain a ﬁrst line of defence to extracellular
athogens both systemically and at mucosal surface and are recog-
ised as serological memory. In contrast, memory-B cells are able
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to provide more antibody-producing cells (ASC) after re-exposure
to speciﬁc antigens or polyclonal stimuli [5,6]. Ideally, vaccination
against N. meningitidis should provide protection for life by the con-
tinuous production of high titers of speciﬁc antibodies or the ability
to respond rapidly to mount for an anamnestic antibody response
[7].
Besides the memory antibody response, the cellular pattern
of immune response has an important role in maintenance of
immunological memory. Three subsets of T-cells have been iden-
tiﬁed based on expression patterns of CD45RA and the chemokine
receptor CCR7 [8]. Two  subsets represent in fact different stages
of maturation with CD45RA−CCR7+ central memory T-cells (TCM)
being the least differentiated, CD45RA−CCR7− effector memory T-
cells (TEM) representing an intermediate stage, and CD45RA+CCR7−
effector terminally differentiated T-cells (TET) being the most dif-
ferentiated ones [9].
Determination  of the expression of surface antigens is an alter-
native method for evaluating the lymphocyte effector function [10].
The CD69 antigen has been identiﬁed as the earliest activation
Open access under the Elsevier OA license.marker on the surfaces of antigen- or allergen-speciﬁc activated
lymphocytes in vitro [11]. Once CD69 is expressed, it acts as
a co-stimulatory molecule for T-cell activation and proliferation
[12].
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Understanding the mechanism by which meningococcal vac-
ines generate and sustain the serological and cellular immune
emory is essential to improving the long-term efﬁcacy of MenB
accines. We  have previously shown that MenB vaccine induced
 strong ASC primary response in mice, but the recall response
howed a limited power over time. Nonetheless, memory B-cells
ere maintained over the time and were probably responsible for
he strong antibody response seen after booster vaccination [13].
In the present study, we investigated the development of long-
erm humoral and cellular (ASC, memory B-cells, memory/effector
-cells) responses after immunisation of health subjects with
he VA-MENGOC-BC® vaccine. Functional antibody analyses were
nvestigated by bactericidal and opsonic assays using the homolo-
ous strain and strains lacking PorA or Opa proteins as the target
trains.
. Subjects and methods
.1.  Study participants
Six  healthy volunteers (5 women and 1 man) aged 23–45 were
nrolled in this study. Vaccination and venipuncture was  done with
he consent of the donors after the nature and possible conse-
uences of the study had been fully explained. Ethical approval was
btained from the HUPE Research Ethics Committee (Protocol num-
er CEP/HUPE: 2743/2010). Exclusion criteria included previous
accination with VA-MENGOC-BC®, use of antibiotics, documented
mmunodeﬁciency, chronic debilitating illness or any past episode
f meningitis.
.2. Vaccination and specimen collection
Following informed consent, the cohort received three doses
f VA-MENGOC-BC®, applied with a 6–8-week interval and a
ooster dose applied 6–7 months after the primary immunisation.
accine was administered by intramuscular injection into the non-
ominant deltoid muscle. Blood was taken before and 3, 7 and 14
ays after each injection of vaccine during the primary immuni-
ation schedule and 6–7 months (pre-booster sample) after the
hird dose. After the booster dose, blood was collected at days 3,
, 14 and 28. A maximum volume of 10 ml  heparinised blood was
vailable for the separation of peripheral blood mononuclear cells
PBMC). PBMCs were separated by density-gradient centrifugation
ver Histopaque® (Sigma, St. Louis, USA). Plasma was collected and
rozen at −20 ◦C.
.3.  Serogroup B meningococcal strains
The Cuban vaccine strain (Cu385/83) of
erotype:serosubtype:immunotype 4,7:P1.19,15:L3,7,9 was
sed for the preparation of outer membrane vesicles (OMV) to
e used as the coat antigen for ELISPOT and as a target strain for
he bactericidal assay. H355/75 (B:15:P1.19,15:L3,7,9,8) and its
ariants PorA− and Opa− were also used for the opsonic and bacte-
icidal antibody assays. The origin of these strains was  previously
escribed [14].
.4.  Detection of plasma cells
PBMCs prepared form peripheral blood were washed in
PMI 1640 (HyClone, Utah, USA) supplemented with 10% fetal
ovine serum (HyClone), 5 ×10−5 -mercaptoethanol (Sigma, St.
ouis, USA) and antibiotics (10,000 U/ml penicillin (Sigma) and
0 mg/ml  streptomycin (Proquímios, Rio de Janeiro, Brazil)) and
e-suspended to a ﬁnal concentration of 1 ×105 PBMC/well. Cells
ere then quantiﬁed by ELISPOT technique as previously described (2011) 7387– 7394
[15].  Brieﬂy, 96-well Maxisorp plates (Nunc, Rochester, USA) were
coated either with 10 g/ml of anti-human IgG monoclonal anti-
body (Kirkegaard & Perry Laboratories, Maryland, USA), or 4 g/ml
of OMV  (Cu385 strain) in 0.05 M Tris buffer, pH 9.5, overnight
at 4 ◦C. After washing with phosphate buffer saline (PBS) 0,01 M,
pH 7.2–7.4, plates were blocked for 1 h with RPMI supplemented
with 1% fetal bovine serum and antibiotics (150 l/well). Then
100 l/well of the cells suspension was added to pre-coated
ELISPOT plates, and incubated for 16 h at 37 ◦C in 5% CO2 and
then washed with PBS/1% Tween 20 (T20). Secreted IgG was
detected with anti-human IgG alkaline phosphatase-conjugated
mAb  (Kirkegaard & Perry Laboratories, Maryland, USA) at a dilu-
tion of 1:5000 in PBS/1% BSA/0.1% T20. ELISPOTs were developed
with 1 mg/ml  5-bromo-4-chloro-3-indolylphosphate (BCIP; Sigma)
dissolved in amino-methyl-propanol buffer (Sigma). Spots were
counted after 2 h by stereoscopic microscopy.
Mean values of spots were calculated from six replicates. OMV
speciﬁc ASC levels were expressed as a percent of total IgG-
secreting B-cells or as a frequency per 2 × 105 PBMC.
2.5. Detection of memory B-cells
PBMCs prepared from peripheral blood were re-suspended
in complete RPMI medium with 10% fetal bovine serum at a
ﬁnal concentration of 1 × 107 PBMC/ml. Five to six replicates of
100 l of cells were added to 96-well ﬂat-bottomed culture plates
followed by 100 l of complete RMPI containing 1/5000 Staphy-
lococcus aureus cells (Cowan 1) (Calbiochem, USA) and 100 IU/ml
interleukin-2 (Calbiochem, USA) [15]. The cells were incubated at
37 ◦C in 5% CO2 for 6 days before being re-suspended and washed
three times in complete medium with 1% fetal bovine serum.
The cultured cells were plated onto pre-coated ELISPOT plates at
2 × 105 cells/well and then incubated and developed as described
for plasma cells.
2.6.  FACS analysis
Freshly  prepared PBMC (1 × 106 cells/100 l) were plated in 96-
well ﬂat-bottom plate in complete RPMI medium, stimulated with
OMV  of Cu385 strain at 50 g/ml or PHA (Sigma) at 10 g/ml or
un-stimulated during incubation for 3 h at 37 ◦C in 5% CO2 atmo-
sphere. Monocuclear cells were pre-incubated with human serum
(1 l/well) for 15 min  at 4 ◦C before staining the cells for surface
markers. Cells were stained for a panel of cell surface markers
including ﬂuorescein isothiocyanate (FITC)-conjugated CD4; phy-
coerythrin (PE)-conjugated CCR7; PerCP-conjugated CD69; and
APC-conjugated CD45RA (all from BD Biosciences Pharmingen, San
Diego, CA). Samples were analyzed on a Becton Dickinson FAC-
Scalibur ﬂow cytometer. On acquisition, a gate was set around the
lymphocyte population on a forward scatter versus side scatter dot
plot, and 10,000-gated events were collected for each sample. Data
analysis was performed using FlowJo software, version 7.6.4. CD4+
T-cells were gated from the lymphocyte population and then ana-
lyzed for the expression of CD45RA, CCR7 and CD69. Appropriate
isotype matched controls (BD) were run in parallel for each sample.
2.7. Bactericidal assay
Serum  bactericidal antibodies were measured as previously
described [14]. Brieﬂy, the ﬁnal reaction mixture contained 25 l of
diluted test serum previously heat inactivated at 56 ◦C for 30 min,
12.5 l of human serum that lacked detectable intrinsic bactericidal
activity diluted at 1:2, and 12.5 l of log phase meningococci (about
5 × 103 CFU/ml) grown on Tryptic Soy Broth (Acumedia Manufac-
tures, Maryland, USA) solidiﬁed with 2% (w/v) Noble agar (Merk)
and containing 1% (v/v) horse serum. The bactericidal reaction was
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arried out at 37 ◦C for 30 min. The CFU per well were determined
ith the aid of a stereoscopic microscope (×40). The bactericidal
iter was deﬁned as the reciprocal of the serum dilution (before
ddition of complement and bacteria) causing ≥50% killing and
ecorded as the log2 titer. A value of 1 was assigned to each titer of
2; thus, log21 = 0. The positive control for each assay consisted of a
ool of post-vaccination mouse serum with previously determined
actericidal titer. The negative control consisted of the complement
ource in the absence of test serum.
.8. Opsonic assay
.8.1.  Protein-coating of latex beads
The protein-coating of latex beads was performed as previously
escribed [16]. Brieﬂy, OMVs from serogroup B meningococci were
dsorbed to ﬂuorescent polystyrene latex microspheres (Fluores-
rite Plain Microspheres, Polysciences, Warrington, Pennsylvania)
f approximately size of meningococci (1 m of diameter). FITC was
ncorporated within the polymer, leaving the surface free to adsorb
he protein. The latex beads (500 l, 4.55 × 1010 beads/ml) were
entrifuged at 15,600 × g for 5 min, and the pellet was  suspended
n a 940 g/ml solution of OMV  in 0.1 M borate buffer (0.1 M boric
cid, adjusted to pH 8.5) followed by end-to-end rotation overnight
20 h) at 20 ◦C. After additional blocking of unreacted sites on the
MV beads with 2% bovine serum albumin (BSA) in 0.1 M borate
uffer, the OMV-bead pellet was suspended in storage buffer (0.1 M
hosphate buffer, containing 5% glycerol, 0.02% merthiolate and 1%
SA, pH 7.4), and kept protected from daylight in aliquots at 4 ◦C
ntil used.
.8.2. Opsonisation and phagocytosis
The antigen coated bead suspensions (100 l,
.3 × 108 beads/ml) were opsonised for 8 min  with 25 l of
iluted test serum (1:20) previously heat inactivated at 56 ◦C
or 30 min, with a total sample volume of 400 l obtained by
ddition of PBS–BSA, supplemented with CaCl2 (0.98 mM)  and
gCl2 (1 mM).  25 l of human serum that lacked detectable
ntrinsic opsonisation activity diluted at 1% was added to the
eaction and were incubated with end-to-end rotation for 8 min
t 37 ◦C. Donor leukocytes (100 l, 1.25 × 107/ml) were added
nd the suspensions were incubated for 8 min. Phagocytosis was
erminated by adding 1.5 ml  of ice-cold PBS supplemented with
.02% EDTA. The suspensions were kept on ice until analyzed by a
ACScalibur ﬂow cytometer [16].
.9. Statistical analysis
The  levels of signiﬁcance of the differences between groups
ere examined by Paired or Unpaired t test (parametric tests)
or nonparametric data we used Mann–Whitney test (unpaired
amples) or Wilcoxon matched pair test (paired samples). These
nalyses were performed with a GraphPad-Prism software, version
.02. P < 0.05 was taken as signiﬁcant.
.  Results
.1. Speciﬁc memory B-cell response to MenB
Fig. 1A shows the percent of speciﬁc memory B-cells detected
s speciﬁc ASC after in vitro stimulation of peripheral blood mem-
ry B-cells for 6 days. Memory B-cells were detected only in one
ndividual 7 days after the ﬁrst dose (0.5%) and in 2 individuals at
4 days (mean of 0.16%). A signiﬁcant memory B-cell response was
een 7 days (mean of 0.27%) and 14 days (mean of 0.46%) after the
hird vaccination. At this time, memory B-cells were detected in (2011) 7387– 7394 7389
all  individuals, with frequencies varying from 0.14 to 0.95%. A sig-
niﬁcant decrease of memory B-cells was  recorded 6 months (mean
of 0.03%) later (pre-booster). Surprisingly, 14 days after the booster
dose, only 2 of 5 individuals responded with an increase in memory
B-cell frequencies with values of 0.15% and 0.34% (mean of 0.1% for
all individuals).
As can be seen in Fig. 1B, we observed a continuous and grad-
ual decrease (P > 0.05) for speciﬁc ASC in blood of vaccinees 7–8
days after each vaccine injection. No signiﬁcant correlations were
detected between memory B-cells and ASC at any time point ana-
lyzed.
These data indicate that three doses of vaccine were necessary
to induce a sufﬁciently robust memory B-cell response which was
of short duration since there was  a weak activation of these cells 6
months later when the booster dose was administered. The reasons
for the gradual decline of speciﬁc ASC in blood are unknown.
3.2.  Bactericidal antibody response
Fig. 2A shows a gradual increase of antibody titers (expressed
as log2 values) after the ﬁrst immunisation measured at 3, 7 and
14 days. The peak of antibody titers was  detected at 14 days with a
median of 2.7 (mean of 3.6, Fig. 2B). Bactericidal titers dropped sig-
niﬁcantly 28 days later (42 days after the ﬁrst dose). The antibody
response was faster after the second dose of vaccine and reached
its maximal at 14 days with a median of 4 (mean of 3.8, Fig. 2B).
Despite the decrease of antibody titers observed 35 days later (49
days after the second dose) 5 of 6 subjects still had bactericidal anti-
body levels above the threshold of protection (titer of 1:4 or log2
of 2). A small increase in antibody levels was seen 14 days after the
third dose of vaccine (median and mean of 4 and 4.7, respectively)
(Fig. 2A and B) with a signiﬁcant decrease 6 months later (median
and mean of 0.5 and 1.5, respectively). The booster dose admin-
istered at this time induced an increase (P = 0.003) in bactericidal
antibody response (median and mean of 2 and 2.6, respectively) but
the boosting response was signiﬁcantly lower than the bactericidal
antibody response induced by 2 or 3 doses of vaccine. Nonetheless,
4 of 5 individuals still had protective antibody titers (Fig. 2B).
Two  of 6 individuals showed the presence of protective bacteri-
cidal titer before vaccination (Fig. 2B). Both individuals had at least
a 4-fold increase in antibody titers after 2 or 3 immunisations.
Thus, one dose of vaccine induced a high bactericidal antibody
response 14 days later. This response slightly increased after 2 and 3
injections of vaccine but was of short duration and was  not strongly
activated by the booster vaccination.
To investigate the role of PorA and Opa proteins on bacterici-
dal antibody titers, we used H355 strain (PorA homologous to the
vaccine strain) and its variants (PorA− and Opa− strains) as the
target strains for the bactericidal assay. As shown in Fig. 2C, serum
samples collected before immunisation had variable antibody titers
against H355 strain, with a mean of 1.7. Three individuals had
bactericidal antibody titers to H355 strain above the protective
threshold titer (log2 ≥ 2). Pre-vaccine antibodies recognised PorA
and Opa proteins since a signiﬁcant decrease in antibody titers
occurred when PorA− and Opa− mutant strains were used as the
target strain (Fig. 2C). Concerning the post-primary immunisation
antibody response to the mutant strains (Fig. 2D), one can clearly
see a signiﬁcant drop in bactericidal antibody titers when the PorA−
but not the Opa− strain was  used as the target strain. These results
indicate a prominent role for PorA, contained in the MenB vaccine,
of inducing bactericidal antibodies.3.3. Opsonic antibody response
Fig.  3A shows the opsonic antibody response to the vaccine
strain measured as median of ﬂuorescence induced during the burst
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Fig. 1. Mean values of (A) speciﬁc ASC from 6 days culture (memory B-cell) against OMV  of MenB:4,7:P1.19,15 (strain Cu385/83) as percent of total IgG-ASC detected in
peripheral blood of volunteers; (B) ASC in blood as number of speciﬁc ASC per 2 ×105 PBMC in well. The lines represent the average response of 6 or 5 individuals for each
time point.
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Fig. 2. Bactericidal antibody response of vaccinated (VAMENGOC-BC® vaccine) volunteers to (A) MenB:4,7:P1.19,15 (Cu385/83 strain). The data show the minimum and
maximal values, the median, and 25 and 75% percentiles of serum bactericidal titers detected several days after each immunisation (total of four); (B) Cu385/83 strain as
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mmunisation and (D) 14 days after the third dose of vaccine. Serum samples of 6
epresents the protective bactericidal titer (1:4 or log2 of 2). The lines represent thexidative of neutrophils. A signiﬁcant increase in opsonic antibody
evels was recorded after 1 or 3 doses (median of 697 and 1395,
espectively) of vaccine. A subsequent decline (P < 0.05) of anti-
ody concentrations (median and mean of 20) was registered 69,15) strain and its mutants lacking PorA or Opa in serum sample collected before
st-booster) individuals were analyzed at each time point. Dashed line in A and B
ge of bactericidal antibody titers.months after the third dose (pre-booster) with a little increase of
antibody levels after the booster dose (median and mean of 20 and
285, respectively). As one can see in Fig. 3B these antibodies were
predominantly directed to PorA protein.
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aig. 3. Opsonic antibody response measured as median of ﬂuorescence induced dur
ere  obtained 14 days after each immunisation and (B) H355/75 (B:15:P1.19,15) s
mmunisation. The line represents the median response of 6 or 5 (post-booster) ind
Overall, signiﬁcant correlations were not found between circu-
ating bactericidal or opsonic antibody titers and frequencies of
emory B-cells, except for positive correlation between opsonic
ntibodies and memory B-cells after the booster dose (r = 0.99,
 = 0.0002). Despite the same kinetics of response, there was  no
orrelation between opsonic and bactericidal antibody titers at any
ime point of the study. These observations are in accordance with
ublished data [15] and suggest the importance of measuring not
nly serum antibodies as a sole marker for vaccine efﬁcacy.
.4.  Memory T-cell response
To  distinguish the putative virgin and memory CD4+ T-cell sub-
ets, we analyzed the expression of CD45RA and CCR7. The virgin
ubset is CD45RA+CCR7+, whereas the memory/effector subsets
re CD45RA−CCR7+ (TCM) or CD45RA−CCR7− (TEM). Because effec-
or terminally differentiated T-cells (TET) can re-express CD45RA,
e also included the T cells CD45RA+CCR7− as TEM. To calculate
he relative frequency of TEM and TCM we considered the sum of
he percentage of the three quadrants representative of the mem-
ry/effector cells as 100%.
Fig.  4A and B shows the mean percentage of TCM and TEM cells,
elative to total memory/activated cells, before and 3 days after
rimary immunisation of volunteers with the MenB vaccine. In
eneral, the frequencies of TEM were higher (P > 0.05) than TCM fre-
uencies. Interestingly, TCM proportions increased (+7%, P > 0.05)
fter OMV  stimulation of cells (mean of 42% versus 35% before stim-
lation). In contrast, the presence of antigen induced a decrease
−6%, P > 0.05) in TEM frequencies from a mean of 64–58%, proba-
ly reﬂecting their terminal differentiation after stimulation. These
ata indicated the speciﬁcity of the reaction, since we  worked
ith the whole population of CD4+ T-cells. About 6 months after
he primary immunisation (day 0 after booster) the percentage of
enB-speciﬁc TCM (mean of 49%) and TEM (mean of 51%) were sim-
lar (Fig. 4C and D). The booster dose induced a gradual increase,
rom 3 days to 14 days, in MenB-TCM reaching statistical signiﬁ-
ance 14 days later (mean of 65%). In contrast, a gradual decrease
as seen for MenB-TEM frequencies at the same period. At 14 days
ost-boosting, MenB-TCM frequencies (mean of 65%) were higher
P < 0.05) than MenB-TEM frequencies (mean of 35%). By 28 days
fter boosting MenB-TCM frequency (mean of 59%) decreased to burst oxidative of neutrophils to (A) the vaccine strain (Cu385/83); serum samples
nd its variants PorA− and Opa−; serum samples were obtained 14 days after third
ls for each time point.
levels  not signiﬁcantly different from the ones detected before
booster (mean of 57% from days 0 to 14) but remained higher
(P < 0.05) than MenB-TEM frequency (mean of 41%). Similar changes
were observed for MenB-TEM frequencies at day 28 (mean of 41%)
which returned to levels statistically similar to pre-boosting (mean
of 51%) (Fig. 4B).
Therefore,  these data indicated that in contrast to the early pri-
mary T-cell response, the 14 day-recall response to vaccination
was marked by a predominance of TCM. This difference may  be
attributed to the fact that the analysis of T-cell frequency after
the primary series was  restricted to a period of 3 days. By day 28,
post-boosting T memory-cells returned to homeostatic levels.
In  agreement with the signiﬁcant increase of MenB-TCM fre-
quency at 14 days after booster immunisation, these cells reached
a maximal (P < 0.05) frequency of activation by day 14 after booster
(mean of 26%) as determined by the expression of CD69 (Fig. 5C).
From days 3 to 14 after boosting frequencies of activated MenB-
TCM (13–26%) were signiﬁcantly higher than activated MenB-TEM
frequencies (5.8–9.2%) (Fig. 5C and D). MenB-TEM reached its maxi-
mal expression of CD69 at day 28 (mean of 14.6%, P < 0.05 compared
to day 14 but not to day 0) after boosting but were still lower in
frequency than the TCM/CD69+ (mean of 22.8%) at the same time
point.
No signiﬁcant differences were seen in activation status of spe-
ciﬁc TCM and TEM after primary immunisation (Fig. 5A and B),
although a discrete increase of TCM/CD69+ was detected after the
third dose (mean of 4.1%) of vaccine when compared with 1 dose
(mean of 2.3%) or before vaccination (mean of 1.3%) (Fig. 5A). Fig. 5B
shows that about 1.7% of TEM cells were activated before or after
immunisation.
In conclusion, vaccination with the Cuban MenB vaccine
induced a signiﬁcant memory CD4+ T-cell population that was acti-
vated by the booster immunisation. As expected for an efﬁcient
recall response, TCM was  readily activated after stimulation with
speciﬁc antigen.
4.  DiscussionThe design of optimal strategies to improve MenB vaccine
efﬁciency is an ongoing challenge [4,17]. We reported here that
the porin PorA, the serosubtype protein of meningococci, had a
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Fig. 4. Mean frequencies (%) and standard error (SEM) of memory CD4+ T-cells in PBMC obtained before and 3 days after primary immunisation (A and B) or before (0) and 3,
7,  14 and 28 days after the booster dose administered at 6–7 months following the third dose of VA-MENGOC-BC® vaccine (C and D). PBMC cells were stimulated (+) or not
w ells (T
C  dose
p 0%.
p
i
v
t
a
t
t
h
p
a
t
r
s
m
c
w
i
(
i
fith OMV  from strain Cu385/83 (MenB:4,7:P1.15,19). (A) Central memory CD4+ T-c
 and D represent TCM and TEM frequencies detected several days after the booster
ercentage of the three quadrants representative of the memory/effector cells as 10
rominent role in inducing bactericidal as well as opsonic antibod-
es after immunisation of volunteers with the VA-MENGOC-BC®
accine. Similarly, previous studies have demonstrated the poten-
ial of PorA, especially loops 1 and 4, for evoke bactericidal
ntibodies [18,19]. In contrast, opsonic antibodies have been shown
o be directed mainly to PorB proteins [20,21].
Maintenance of long-term antibody responses is critical for pro-
ective immunity against N. meningitidis. However, the duration of
umoral immunity and the role played by memory B-cells remain
oorly deﬁned. Memory B-cell developmental program requires
ntigen-speciﬁc CD4+ T-cell help [22]. A reported study showed
hat children of all ages can produce in vitro cellular immune
esponses following meningococcal infection [23]. To better under-
tand the potential of the Cuban vaccine to induce immunological
emory we performed a longitudinal analysis of memory B-
ell frequency, the kinetics of functional antibody response as
ell as the memory T-cell frequencies and activation status after
mmunisation of adult volunteers with the Cuban MenB vaccine
VA-MENGOC-BC®).
Despite the small number of individuals in this study, our results
ndicated a short duration of the humoral immunity in terms of both
requency of memory B-cells and functional antibody titers. TheCM; CD45RA−CCR7+) and (B) effector memory CD4+ T-cells (TEM; CD45RA−/+CCR7−).
. To calculate the relative frequency of TEM and TCM we considered the sum of the
frequencies  of memory B-cells varied from 0.14% to 0.95% (median
of 0.46%) 14 days after the third vaccination. This is in agreement
with results of Sasaki at al. [24], who  found a rather constant fre-
quency of approximately 0.5% inﬂuenza-speciﬁc memory B-cells in
circulating blood from 27 to 42 days after vaccination. However, for
5 out of 6 individuals, the MenB speciﬁc memory B-cells declined to
undetectable values 6 months after the primary series. The booster
dose induced a recall response only in 2 of 5 individuals. These data
are in contrast with the results of Nanan et al. [15] who showed that
speciﬁc memory B-cells accumulate with every immunisation dose
of tetanus or diphtheria vaccine and remain elevated over several
years. Similar to the memory B-cell response, post-boosting bacte-
ricidal antibody levels were signiﬁcantly lower than after 3 doses
of vaccine, with 3 of 5 individuals presenting a 4-fold increase in
antibody titers. A similar antibody response pattern was  observed
for opsonic antibodies.
Due  to the continuous re-circulation of memory B-cells through
the blood and secondary lymphoid organs it is assumed that mem-
ory B-cells found in the circulation should be representative for
the entire B-cell pool [15,25]. A recent report of long-term pres-
ence of memory B-cells speciﬁc for tetanus, pertussis, measles and
inﬂuenza virus found that the frequencies of these cells varied
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Fig. 5. Mean percentage of memory T (CD4+) cells expressing the CD69 molecule, a marker for recent cell activation, after primary immunisation (A and B) and after the
booster dose administered at 6–7 months after the third dose of VA-MENGOC-BC® vaccine (C and D). Cells were stimulated for 3 h or not with OMV  and % of CD69+ cells
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nalues were calculated after subtraction of % of CD69 cells in un-stimulated cont
fter each dose and (B) frequency of effector memory T cells (TEM; CD45RA−/+CCR7−
efore (0) and 3, 7, 14 and 28 days after the booster dose.
etween 0.02% and 0.87% of the total IgG producing cells. Of note,
emory B-cells were detected in all individuals for all antigens
ested [25], indicating a high sensitivity of the assay, which used
pG, IL-2, IL-10 and IL-15 as polyclonal stimulators of B-cells. The
ssay used in our study may  be of lower sensitivity compared with
he latter, since we used only IL-2 and SAC as polyclonal stimu-
ators of B-cells. Nonetheless, our results showed that the proﬁle
f memory B-cell response of vaccinated volunteers was  kinet-
cally accompanied by serum bactericidal and opsonic antibody
esponses indicating the presence of short lived memory B-cells or
oor activation of these cells. Further cellular studies are needed to
nderstand how MenB OMV  antigens could mediate the induction
f effective primary B-cell response with limited memory capacity.
A study described by Luijkx et al. [26] showed that mouse B-cell
ubpopulations involved in a successfully bactericidal and afﬁnity
aturated antibody response to PorA P1.5-1,2-2 are maintained
t smaller population sizes than those associated with poor anti-
ody response to PorA P1.7-2,4. Our human and mouse antibody
tudies have shown a strong immunogenicity of PorA P1.19,15 pro-
ein [14,18,27]. This protein has also induced a robust speciﬁc ASC
esponse in mouse spleen and bone marrow after primary immu-
isation, but not after boosting [13]. Moreover, a constant level) Frequency of central memory T cells (TCM; CD45RA CCR7 ) CD69 cells, 3 days
9+ cells, 3 days after each dose. C and D represent TCM and TEM frequencies detected
of  about 1% of speciﬁc spleen memory B-cells was  detected after
primary and booster immunisation [13]. Thus, our human and ani-
mal  studies with the VA-MENGOC-BC® vaccine showed a lower
or an unaltered B-cell response (ASC and/or memory B-cell) after
boosting, suggesting some limitations in the long-term effect of
vaccination.
Speciﬁc CD4+ T-cells found in naive, TCM, or TEM populations
largely differ in their functional properties, such as antigen require-
ment for maximal efﬁciency, effector activity (level of cytokine
secretion, co-stimulatory molecule expression), replicative activ-
ity, and/or life span [8,9]. Speciﬁc T-cell expansion of either
population may  therefore inﬂuence the protective efﬁcacy of the
pathogen-targeted, speciﬁc immune response. Three days after
the primary immunisation schedule we observed a slightly pre-
dominant TEM (CD45RA−/+CCR7−) response (mean of 58% when
stimulated by OMV), with a discrete proportion (mean of 1.7%) of
activated cells (CD69+). Cell activation was slightly higher (mean
of 4.1%) for TCM (CD45RA−CCR7+) which was presented in a mean
proportion of 42%. However, after boosting, a predominant expan-
sion of the TCM population was  observed (mean of 57%) paralleled
by a continuous decrease of TEM (mean of 42%) up to 14 days. As
indicated by the expression of CD69, activated cells were mainly
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eported after recall immunisation with tetanus toxoid [28]. Thus,
hese data showed that the T-cell response to vaccination had a
ifferent kinetics of the B-cell response, which was higher after
rimary immunisation and declined after boosting. The question
rises how T-B-cell interactions differ after primary and booster
accination with the OMV  vaccine.The neisserial porins are the
ajor protein components of OMV  present in the Cuban MenB
accine. They have been shown to be able to enhance the immune
esponse to poorly immunogenic substances (e.g., polysaccharides)
nd up regulation of B7-2 on the surface of B lymphocytes may
e the mechanism behind this immune-potentiating activity [29].
owever, B-cells also have a role to act as a counter regulatory in
alancing pathogen-speciﬁc immune responses. B-cells activated
y Helicobacter TLR-2 ligands induce IL-10-producing CD4+CD25+
 regulatory-1 (Tr-1)-like cells in vitro and in vivo [30]. Tr-1 con-
ersion depends on TCR signaling and a direct T-/B-interaction
hrough CD40/CD40L and B7-1/CD28. B cell-induced Tr-1 cells
cquire suppressive activity in vitro and in vivo. In addition, sys-
emic injection of Pam2 lipopeptides (a TLR-2 ligand) induced IL-10
n a TLR2-dependent manner [31]. The Pam2 lipopeptides increased
he frequencies of Foxp3+CD4+ regulatory T (T reg) cells in a TLR2-
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In  conclusion, this study suggests that vaccination with the
A-MENGOC-BC® induced a robust immune response after three
njections of vaccine. Vaccination induced the generation and acti-
ation of memory T-cells after primary and booster schedules
ut failed to maintain a memory B-cell population at a stable
ize and/or functionality. The weak boosting antibody response
einforces suboptimal recall functions of the remaining memory
-cell population. More studies are needed in view of the scarce
nowledge about cellular mechanisms of antibody response and
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